{"id":"W1998765648","doi":"10.1016/j.jalz.2011.05.2250","title":"P4‐225: A confirmatory phase 3 randomized, double‐blind, placebo‐controlled study of the safety and effectiveness of immune globulin intravenous (Human), 10% solution (GAMMAGARD LIQUID/KIOVIG) for the treatment of mild to moderate Alzheimer's disease","year":2011,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Placebo; Medicine; Clinical endpoint; Randomized controlled trial; Clinical trial; Internal medicine; Surrogate endpoint; Tolerability; Adverse effect; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00189114,0.003143495,0.002609898,0.0006968453,0.0007187778,0.001249139,0.001530182,0.002987941,0.009572858],"category_scores_gemma":[0.001333778,0.0009143727,0.001778627,0.0003352232,0.001575324,0.001087044,0.0004514036,0.004319082,0.002219602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007108306,"about_ca_system_score_gemma":0.002400951,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001041383,"about_ca_topic_score_gemma":0.001892633,"domain_scores_codex":[0.9993274,0.0003085651,0.00003257572,0.0001145079,0.00008857526,0.0001284196],"domain_scores_gemma":[0.9992371,0.0001463154,0.0001591262,0.00006328421,0.00007506947,0.0003191507],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9051194,0.0378824,0.000524563,0.001191736,0.0008434888,0.0001572961,0.000106745,0.0004592386,0.01573624,0.0004265815,0.004683148,0.03286928],"study_design_scores_gemma":[0.8667508,0.128727,0.001053591,0.0000241932,0.0001701032,0.00004989406,0.00001329996,0.0003023021,0.00130051,0.0002023293,0.001385183,0.00002068774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9499363,0.003574961,0.002943889,0.001636891,0.0007179701,0.02890265,0.004464185,0.0009620797,0.00686107],"genre_scores_gemma":[0.9418685,0.002673977,0.006300465,0.004213011,0.0006647079,0.02835639,0.004096133,0.0001309577,0.01169581],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009572858,"threshold_uncertainty_score":0.03202444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05435357268236754,"score_gpt":0.3338438189454593,"score_spread":0.2794902462630917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}